207 related articles for article (PubMed ID: 27022131)
1. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
[TBL] [Abstract][Full Text] [Related]
2. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.
Warso MA; Richards JM; Mehta D; Christov K; Schaeffer C; Rae Bressler L; Yamada T; Majumdar D; Kennedy SA; Beattie CW; Das Gupta TK
Br J Cancer; 2013 Mar; 108(5):1061-70. PubMed ID: 23449360
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.
Jia L; Gorman GS; Coward LU; Noker PE; McCormick D; Horn TL; Harder JB; Muzzio M; Prabhakar B; Ganesh B; Das Gupta TK; Beattie CW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):513-24. PubMed ID: 21085965
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial.
Fangusaro J; Mitchell DA; Kocak M; Robinson GW; Baxter PA; Hwang EI; Huang J; Onar-Thomas A; Dunkel IJ; Fouladi M; Warren KE
Pediatr Blood Cancer; 2021 Feb; 68(2):e28756. PubMed ID: 33025730
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
Kieran MW; Packer RJ; Onar A; Blaney SM; Phillips P; Pollack IF; Geyer JR; Gururangan S; Banerjee A; Goldman S; Turner CD; Belasco JB; Broniscer A; Zhu Y; Frank E; Kirschmeier P; Statkevich P; Yver A; Boyett JM; Kun LE
J Clin Oncol; 2007 Jul; 25(21):3137-43. PubMed ID: 17634493
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE
J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
[TBL] [Abstract][Full Text] [Related]
9. Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report.
Leary SES; Park JR; Reid JM; Ralya AT; Baruchel S; Wu B; Roberts TPL; Liu X; Minard CG; Fox E; Weigel B; Blaney S
Clin Cancer Res; 2017 Oct; 23(20):6062-6069. PubMed ID: 28751444
[No Abstract] [Full Text] [Related]
10. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.
Packer RJ; Rood BR; Turner DC; Stewart CF; Fisher M; Smith C; Young-Pouissant T; Goldman S; Lulla R; Banerjee A; Pollack I; Kun L; Onar-Thomas A; Wu S; Boyett JM; Fouladi M
J Neurooncol; 2015 Jan; 121(1):217-24. PubMed ID: 25407389
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
Kieran MW; Chi S; Goldman S; Onar-Thomas A; Poussaint TY; Vajapeyam S; Fahey F; Wu S; Turner DC; Stewart CF; Moses M; Packer RJ; Jakacki R; Banerjee A; Boyett JM; Fouladi M; Kun L
Childs Nerv Syst; 2015 Sep; 31(9):1433-45. PubMed ID: 26188774
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Fouladi M; Stewart CF; Olson J; Wagner LM; Onar-Thomas A; Kocak M; Packer RJ; Goldman S; Gururangan S; Gajjar A; Demuth T; Kun LE; Boyett JM; Gilbertson RJ
J Clin Oncol; 2011 Sep; 29(26):3529-34. PubMed ID: 21825264
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors.
Robison NJ; Yeo KK; Berliner AP; Malvar J; Sheard MA; Margol AS; Seeger RC; Rushing T; Finlay JL; Sposto R; Dhall G
J Neurooncol; 2018 May; 138(1):199-207. PubMed ID: 29427149
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Hoffman LM; Fouladi M; Olson J; Daryani VM; Stewart CF; Wetmore C; Kocak M; Onar-Thomas A; Wagner L; Gururangan S; Packer RJ; Blaney SM; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
Childs Nerv Syst; 2015 Aug; 31(8):1283-9. PubMed ID: 25930724
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
Kilburn LB; Kocak M; Decker RL; Wetmore C; Chintagumpala M; Su J; Goldman S; Banerjee A; Gilbertson R; Fouladi M; Kun L; Boyett JM; Blaney SM
Neuro Oncol; 2015 Feb; 17(2):303-11. PubMed ID: 25431212
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).
Loh ML; Tasian SK; Rabin KR; Brown P; Magoon D; Reid JM; Chen X; Ahern CH; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2015 Oct; 62(10):1717-24. PubMed ID: 25976292
[TBL] [Abstract][Full Text] [Related]
19. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
[TBL] [Abstract][Full Text] [Related]
20. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
